Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: A multicentre open clinical trial

Seizure

Volumn 11, Issue 4, 2002, Pages 255-260

  Lee, Byung In ^a   Heo, Kyoung ^a   Kim, Won Joo ^a   Kim, Dong Kee ^a   Shin, Dong Jin ^a   Kim, Kwang Soo ^a   Lee, Sang Do ^a   Kim, Joo Uhn ^a   Lee, Keun Ho ^a   Oh, Hee Jong ^a   Kim, Sang Ho ^a   Park, Sung Ho ^a   Nam, Hyun Woo ^a   No, Soon Ki ^a   Chung, Dae Soo ^a   Park, Hyung Kuk ^a   Lee, Sang Kun ^a   Hong, Seung Bong ^a   Suh, Dae Won ^a   Lee, Sung Soo ^a   Lee, Sang Am ^a   Kang, Joong Ku ^a   Park, Je Hyun ^a   Kim, Jung Yun ^a   Kim, Sug Eun ^a   Lee II, Keun ^a   Kim, Young Hyun ^a   Kim, Jae Moon ^a   Song, Hong Ki ^a   Lee, Chong Sub ^a   more..

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Efficacy; Safety; Slow titration; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AMNESIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; FREQUENCY ANALYSIS; HEADACHE; HUMAN; INCIDENCE; INTRACTABLE EPILEPSY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; SOMNOLENCE; STATISTICAL ANALYSIS; TITRIMETRY; VERTIGO; VISUAL DISORDER; WEIGHT REDUCTION;

EID: 0036306502     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2001.0605     Document Type: Article

References (18)

1. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
2. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400, and 600 mg daily dosages
3. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600, 800 and 1000 mg daily dosage
4. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset epilepsy
5. Double blind, placebo-controlled study in patients with refractory partial epilepsy
6. Double-blind placebo-controlled trial of topiramate (600 mg daily) for treatment of refractory partial epilepsy
7. A pharmacological and clinical review on topiramate, a new antiepileptic drug
8. The new antiepileptic drugs: A systematic review of their efficacy and tolerability
9. Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adults
10. Safety of topiramate: Adverse events and relationships to dosing
11. The beneficial effect of slowing the initial titration rate of topiramate
12. Onset of anticonvulsant effect of topiramate, a new antiepileptic drug (AED)
13. Practical aspects of the use of topiramate in patients with epilepsy
14. Topiramate in medically intractable partial epilepsies: Double-blind placebo-controlled randomized parallel group trial
15. Topiramate in refractory epilepsy: A prospective observational study
16. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy
17. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures
18. Early identification of refractory epilepsy